Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Regulation of neuroprotective pathways in Multiple Sclerosis models
EF 2013-14
Résumé
Neurodegenerative diseases are extremely common debilitating conditions and represent one of the leading medical and societal challenges in Canada. One of these conditions, Multiple Sclerosis (MS), is the most common neurological disease of young adults in Canada, currently affecting an estimated 100,000 people. Worldwide, roughly 2.3 million people are living with MS. MS is an inflammatory and demyelinating neurodegenerative disorder of the brain and spinal cord with a wide range of severe symptoms, including loss of balance, impaired vision or speech, extreme fatigue and paralysis. Current MS treatments focus on blocking inflammation, and fall under two categories: those well tolerated but only partially effective, or those with greater effectiveness but increased risk. For this reason, research focusing on therapies for protecting nerves and limiting inflammation is highly crucial.
Our lab has become interested in two proteins with known roles in nerve survival called Npas4 and ARNT2. Previous work has highlighted the protective properties of these proteins on nerves during stroke and also in a laboratory setting. However, their role in neurodegenerative disease has not yet been characterized. Our lab has previously shown that early on in models of the disease levels of Npas4 and ARNT2 are very high before the clinical symptoms of MS appear, but decrease by disease onset and as symptoms become most severe. As well, when an antioxidant drug was administered, levels of these proteins were higher, and milder clinical disease was seen, suggesting a potentially therapeutic role for Npas4 and ARNT2 in inflammatory neurodegenerative disease. In this project, we aim to further investigate the regulation of these nerve-protecting (or neuroprotective) proteins in models of MS, and to also apply our findings to other neurodegenerative diseases. We believe that the regulation of Npas4 and ARNT2 correlates with disease development in models of MS and that their expression is similar to what is observed in MS patients. Also, we believe that Npas4 and ARNT2 are influenced by immune cells that enter the brain in MS, thereby affecting nerve survival. To test our theories we will first localize Npas4 and ARNT2, and compare their levels to what is seen in MS relative to stroke and other neurodegenerative diseases. As well, we will examine the ability of immune cells and other nerve cell stressors to change Npas4 or ARNT2 expression. Additional studies will investigate how regulating Npas4 and ARNT2 levels alters the function of nerve cells and their ability to survive and grow.
Enhancing our understanding of neuroprotective pathways remains a major goal in identifying novel therapeutics to limit disease severity, recurrence and progression in MS. This project will further characterize the ability of Npas4 and ARNT2 to influence, or be influenced by, inflammatory and neurodegenerative processes, and warrants their consideration in the development of neuroprotective therapies in MS.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311780
Name
Rahim Tissa
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Regulation of neuroprotective pathways in Multiple Sclerosis models
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunology; Molecular And Cellular Biology; Molecular Protective Pathways; Nervous System; Neurodegeneration; Neuropathology; Neuroprotection And Regeneration
Abstract
Neurodegenerative diseases are extremely common debilitating conditions and represent one of the leading medical and societal challenges in Canada. One of these conditions, Multiple Sclerosis (MS), is the most common neurological disease of young adults in Canada, currently affecting an estimated 100,000 people. Worldwide, roughly 2.3 million people are living with MS. MS is an inflammatory and demyelinating neurodegenerative disorder of the brain and spinal cord with a wide range of severe symptoms, including loss of balance, impaired vision or speech, extreme fatigue and paralysis. Current MS treatments focus on blocking inflammation, and fall under two categories: those well tolerated but only partially effective, or those with greater effectiveness but increased risk. For this reason, research focusing on therapies for protecting nerves and limiting inflammation is highly crucial.
Our lab has become interested in two proteins with known roles in nerve survival called Npas4 and ARNT2. Previous work has highlighted the protective properties of these proteins on nerves during stroke and also in a laboratory setting. However, their role in neurodegenerative disease has not yet been characterized. Our lab has previously shown that early on in models of the disease levels of Npas4 and ARNT2 are very high before the clinical symptoms of MS appear, but decrease by disease onset and as symptoms become most severe. As well, when an antioxidant drug was administered, levels of these proteins were higher, and milder clinical disease was seen, suggesting a potentially therapeutic role for Npas4 and ARNT2 in inflammatory neurodegenerative disease. In this project, we aim to further investigate the regulation of these nerve-protecting (or neuroprotective) proteins in models of MS, and to also apply our findings to other neurodegenerative diseases. We believe that the regulation of Npas4 and ARNT2 correlates with disease development in models of MS and that their expression is similar to what is observed in MS patients. Also, we believe that Npas4 and ARNT2 are influenced by immune cells that enter the brain in MS, thereby affecting nerve survival. To test our theories we will first localize Npas4 and ARNT2, and compare their levels to what is seen in MS relative to stroke and other neurodegenerative diseases. As well, we will examine the ability of immune cells and other nerve cell stressors to change Npas4 or ARNT2 expression. Additional studies will investigate how regulating Npas4 and ARNT2 levels alters the function of nerve cells and their ability to survive and grow.
Enhancing our understanding of neuroprotective pathways remains a major goal in identifying novel therapeutics to limit disease severity, recurrence and progression in MS. This project will further characterize the ability of Npas4 and ARNT2 to influence, or be influenced by, inflammatory and neurodegenerative processes, and warrants their consideration in the development of neuroprotective therapies in MS.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rahim, Tissa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~